🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

24+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 24 recruiting trials for “toxic-dermatosis

Phase 2, PHASE3RecruitingNCT07160205

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

👨‍⚕️ Michael Bubb, MD, Malcom Randall North Florida/South Georgia VA Medical Center📍 2 sites📅 Started Jan 2026View details ↗
NARecruitingNCT07377058

RCT of Tocilizumab for Anti-MDA5+DM

🏥 Peking Union Medical College Hospital📍 1 site📅 Started Nov 2025View details ↗
RecruitingNCT07345949

Panniculitis in Dermatomyositis

🏥 University Hospital, Strasbourg, France📍 1 site📅 Started Oct 2025View details ↗
Phase 2RecruitingNCT06857240

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

👨‍⚕️ Anthony Fernandez, MD, The Cleveland Clinic📍 1 site📅 Started Jun 2025View details ↗
Phase 1RecruitingNCT06919380

Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial

🏥 Li Shiyue📍 1 site📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT06672822

Intralesional Injection of STS in Treatment of Calcinosis

👨‍⚕️ Robyn T Domsis, MD, University of Pittsburgh📍 1 site📅 Started Mar 2025View details ↗
Phase 3RecruitingNCT06698796

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

👨‍⚕️ Pfizer CT.gov Call Center, Pfizer📍 22 sites📅 Started Jan 2025View details ↗
Phase 1RecruitingNCT06686524

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

🏥 Chongqing Precision Biotech Co., Ltd📍 1 site📅 Started Nov 2024View details ↗
Phase 1RecruitingNCT06298019

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

👨‍⚕️ David Fiorentino, MD, PhD, Stanford University📍 2 sites📅 Started Aug 2024View details ↗
Phase 1RecruitingNCT06569472

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

👨‍⚕️ Meiping Lu, M.D, Children's Hospital, Zhejiang University School of Medicine📍 1 site📅 Started Jul 2024View details ↗
Phase 3RecruitingNCT06455449

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

🏥 AstraZeneca📍 228 sites📅 Started Jun 2024View details ↗
Phase 4Enrolling by InvitationNCT06438679

3T Therapy in the Treatment of MDA5-positive Dermatomyositis

🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Mar 2024View details ↗
RecruitingNCT06203249

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

🏥 Chinese PLA General Hospital📍 1 site📅 Started Jan 2024View details ↗
NARecruitingNCT07037472

Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation

🏥 Peking Union Medical College Hospital📍 1 site📅 Started Jan 2024View details ↗
RecruitingNCT06004817

Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis

👨‍⚕️ Paul Decker, MD, CHU NANCY📍 1 site📅 Started Oct 2023View details ↗
Phase 3RecruitingNCT05895786

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

👨‍⚕️ Pfizer CT.gov Call Center, Pfizer📍 139 sites📅 Started May 2023View details ↗
Phase 3Enrolling by InvitationNCT05495321

Interleukin-2 on Active Dermatomyositis

👨‍⚕️ Zhanguo Li, Peking University People's Hospital📍 1 site📅 Started Dec 2022View details ↗
Phase 3RecruitingNCT04972760

Baricitinib in Patients With Relapsing or naïve Dermatomyositis

👨‍⚕️ YVES ALLENBACH, MD, PhD, Assistance Publique Hopitaux de Paris📍 1 site📅 Started Aug 2022View details ↗
RecruitingNCT07265999

Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES

👨‍⚕️ nadège cordel, MD PhD, CHU de la Guadeloupe📍 1 site📅 Started Jul 2021View details ↗
Phase 2RecruitingNCT03582800

Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study

👨‍⚕️ Vincent GUIGONIS, MD, University Hospital, Limoges📍 8 sites📅 Started Jan 2020View details ↗
Page 1 of 2Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →